X

Drug Profile

Dabrafenib - Rescindo Therapeutics

Alternative Names: RSC-57

Latest Information Update: 12 Apr 2022

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Rescindo Therapeutics
Class Fluorobenzenes; Pyrimidines; Small molecules; Sulfonamides; Thiazoles
Mechanism of Action Proto-oncogene protein b-raf inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Kabuki syndrome
New Molecular Entity No

Highest Development Phases

Preclinical Kabuki syndrome

Most Recent Events

05 Apr 2022 Preclinical trials in Kabuki syndrome in USA (Unspecified) (Rescindo Therapeutics pipeline, March 2022)
12 Feb 2021 RSC 57 receives Orphan Drug status for Kabuki syndrome in USA
12 Feb 2021 RSC 57 receives rare paediatric disease designation from the FDA for Kabuki syndrome

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com